Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

PSNI appoints Michaela McAleer as its new chief executive

The Pharmaceutical Society NI (PSNI) has announced that Michaela McAleer will be replacing Trevor Patterson as Chief Executive of PSNI.

After 15 years at the helm, Patterson announced his intention to retire. Jonathan Patton, Vice President of the Society said, “Joining the Society from the construction sector Trevor brought fresh thinking and vigour to the Society and quickly established his credibility with pharmacists, Council, stakeholders and fellow regulatory bodies.”


“Trevor has presided over tremendous change and development through his tenure with equal measures of professionalism and passion on creating safer protections for the public and ensuring pharmacists achieved world class standards in their profession. We are saddened to see him depart but on behalf of Council I wish him a long and healthy retirement and wish him well in the next chapter of life. We are indebted to him for his dedication to the Pharmaceutical Society NI.”

“Losing the constant and continuity of our 15 year serving Chief Executive ushers in a time of change and evolution for us as the Pharmacy Regulator. We are in the midst of a fast moving and changing environment as we implement continuous improvement.

McAleer will take up her appointment on 5th December 2022, on her appointment Patton commented: “The experience Michaela brings with her from her extensive roles in Regulation provides the Society and the public with the assurance that the evolution will continue at pace and that we will strengthen the already strong relationships and professionalism we bring to the world of Pharmacy. Staff and Council are looking forward to working with her and progressing the exciting and important work of the Pharmaceutical Society.”

Michaela McAleer brings to the role 20 years public sector experience in the oversight of public bodies through independent investigation of complaints and the regulation of statutory codes of conduct. (Formerly, the Acting Deputy Commissioner for Local Government Standards at the Northern Ireland Public Services Ombudsman she has investigated alleged breaches of the Code of Conduct for Northern Ireland Councillors and led the first ‘Own Investigation’ undertaken by a UK Ombudsman under new statutory powers introduced in April 2018.)

More recently she has extended her experience in regulation to include that of the UK press and serves as a non executive director for the Independent Press Standards Organisation.

Michaela McAleer said: “I am delighted to be taking on the role of Chief Executive at this challenging time for pharmacists and the health system across the region. I am looking forward to working alongside the new President of the Council and its members continuing and building upon the work of the current Chief Executive, Trevor Patterson, regulating to ensure the delivery of safe and trusted care to the public by the pharmacy profession”.

More For You

NHS app to boost clinical trials

The focus is on encouraging people from underrepresented groups, including minorities from African and Asian heritage, to sign up for clinical trials.

iStock

Government to use NHS app to boost clinical trials

The government’s 10-Year Health Plan is expected to provide a fillip to clinical trials, and it plans to make use of the NHS App to encourage people to sign up as participants.

People will be able to sign up for the NIHR Be Part of Research service (bepartofresearch.uk) on the NHS App for the trials best suited to their interests and needs.

Keep ReadingShow less
US pharma bets big on China to snap up potential blockbuster drugs

Through June, US drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies

US pharma bets big on China to snap up potential blockbuster drugs

US drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.

Through June, US drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to Reuters.

Keep ReadingShow less
Alliance Healthcare team raises thousands with charity bike ride to Paris

The Alliance Healthcare team

Alliance Healthcare team raises thousands with charity bike ride to Paris

Eight Alliance Healthcare team members raised over £55,000 for Theodora Children’s Charity by cycling from Surrey to Paris.

From June 13th-15th, the team took on the gruelling 300 mile cross-border Tour D’Alliance 2025 challenge and raised vital funds to support children who may be living with serious health challenges through Theodora Children’s Charity’s Giggle Doctor programme.

Keep ReadingShow less
Over four million flu vaccines across England in the 2024/25 winter flu season.

Over four million flu vaccines across England in the 2024/25 winter flu season.

CCA release

Community pharmacy administered over four million flu vaccines

Community pharmacy administered over four million flu vaccines across England in the 2024/25 winter flu season, the highest outside of the pandemic, according to the Company Chemists’ Association.

This is nearly 10 per cent higher than the number of flu vaccines administered in 2023/24.

Keep ReadingShow less
Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less